Pricing Log in Create free account
Saturday 17 October 2026 Export VCYT’s income statement to Excel — free account

Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 21.03
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 8 6 — — 5 — 3 5 — — 6 —
Insider Ownership 1.32%

Capital & Financial Ratios $m

Market Cap 3,570.00
Revenue 561.90
Net Income 114.48
Free Cash Flow 165.99
Net Debt (485.23)
Current Ratio 9.16 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 29.94
Fwd P/E 45.10 (above 35: high)
P/S ratio 6.14
P/B ratio 2.48
Past 5Y EPS Growth —
This Y EPS Growth 7.47%
Next Y EPS Growth 1.72%
Next Y revenue growth 14.80% (at or above 10%: strong)
Next 5Y EPS Growth 5.34%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.3×, against a ten-year median of 5.2×; over the ten years it ranged from 2.3× in 2016 to 25.1× in 2021.
P/S against its own 10 years 56.40%
10-year low 10-year high
P/B against its own 10 years 38.30%
10-year low 10-year high
EV/Sales against its own 10 years 52.97%
10-year low 10-year high
EV/FCF against its own 10 years 7.64%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 216 289 413 485
Receivables 40 47 45 54
Inventory 16 22 21 23
Other — — — —
286 372 488 575
2023 2024 2025 Q'26
Payables 13 9 5 8
ST’ Debt — — — —
Other 3 17 1 1
61 79 60 63

Compound Annual Growth %

10y 5y 3y
Sales 26.44% 34.50% 20.37%
Cash Flow 0.00% 0.00% 162.51%
Earnings 0.00% 0.00% 0.00%
Book Value 38.27% 25.46% 6.79%

Revenue $m

Mar Jun Sep Dec Year
’26 139 150 — — —
’25 114 130 132 141 517
’24 97 114 116 119 446
’23 82 90 90 98 361
’22 68 73 76 80 297
’21 37 55 60 67 220
’20 31 21 31 35 117
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 35 46 — — —
’25 5 34 45 53 136
’24 (9) 30 30 25 75
’23 (2) 17 14 16 44
’22 (9) 0 7 10 8
’21 (41) 2 (1) 8 (32)
’20 (5) (8) 2 2 (10)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 32 43 — — —
’25 4 32 42 49 127
’24 (11) 27 28 20 64
’23 (3) 13 11 13 34
’22 (11) (3) 5 8 (1)
’21 (42) 0 (3) 8 (37)
’20 (6) (9) 1 1 (13)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.35 0.31 — — —
’25 0.09 (0.01) 0.24 0.51 0.82
’24 (0.02) 0.07 0.19 0.06 0.31
’23 (0.11) (0.12) (0.41) (0.39) (1.02)
’22 (0.20) (0.13) (0.12) (0.05) (0.51)
’21 (0.66) (0.13) (0.20) (0.15) (1.11)
’20 (0.24) (0.22) (0.08) (0.14) (0.66)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.21 5.75 5.23 11.70 13.90 32.87 14.85 19.52 18.61 22.61

Analyst estimates 2026–2028

Powerpack
High 8.45 9.80 15.50 31.18 63.55 86.03 42.95 30.52 46.00 50.71
People
People Employees 216 246 270 354 320 761 787 815 824 755
Revenue/emp, $m 0.30 0.29 0.34 0.34 0.37 0.29 0.38 0.44 0.54 0.68
Income, $m
Income, $m Revenue 65 72 92 120 117 220 297 361 446 517
Gross margin, % 60.88 60.81 64.05 69.66 64.71 66.11 59.24 63.62 66.88 70.10
EBT (31) (31) (23) (13) (35) (82) (36) (77) 26 68
EBT margin, % (48.18) (43.09) (25.00) (10.47) (29.71) (37.20) (12.28) (21.22) 5.78 13.19
Net income (31) (31) (23) (13) (35) (76) (37) (74) 24 66
Depreciation 3 4 4 4 8 20 26 27 23 18
Per share, $
Per share, $ Revenue 2.26 2.12 2.49 2.61 2.21 3.23 4.14 4.97 5.83 6.58
Earnings (1.09) (0.91) (0.62) (0.27) (0.66) (1.11) (0.51) (1.02) 0.32 0.84
Cash flow (0.97) (0.70) (0.37) (0.07) (0.18) (0.47) 0.11 0.61 0.98 1.73
Capex (0.15) (0.04) (0.05) (0.06) (0.05) (0.08) (0.12) (0.14) (0.15) (0.12)
Free cash flow (1.12) (0.74) (0.42) (0.13) (0.24) (0.54) (0.01) 0.47 0.83 1.61
Book value 2.07 1.10 2.15 5.19 7.91 16.15 15.03 14.37 15.38 16.66
Shares, m 29 34 37 46 53 68 72 73 76 79
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 123.75 50.12
P/S 3.48 3.17 5.06 10.70 22.18 12.74 5.47 5.51 6.79 6.40
P/B 3.80 6.12 5.84 5.38 6.19 2.55 1.51 1.91 2.58 2.53
EV/Sales 2.98 3.07 4.49 9.40 19.23 11.95 4.87 4.92 6.15 5.60
EV/FCF (6.02) (8.75) (26.83) (189.60) (180.03) (70.87) (1,424.06) 51.84 42.97 22.88
Cash, $m
Cash, $m Operating cash flow (28) (24) (14) (3) (10) (32) 8 44 75 136
Capex (4) (1) (2) (3) (3) (5) (9) (10) (11) (10)
Free cash flow (32) (25) (15) (6) (13) (37) (1) 34 64 127
Balance, $m
Balance, $m Working capital 62 42 84 170 359 179 186 224 294 428
Total debt 26 25 25 2 3 1 15 — — —
Net debt (34) (9) (53) (158) (347) (176) (179) (216) (289) (413)
Shareholders’ equity 60 37 80 239 421 1,097 1,075 1,044 1,176 1,310
Returns, %
Returns, % ROA (35.58) (34.50) (23.08) (6.37) (9.53) (9.19) (3.12) (6.55) 2.00 4.90
ROIC (69.89) (58.03) (51.39) (11.55) (29.62) (5.56) (2.86) (6.48) 1.14 4.03
ROE (56.59) (64.05) (39.32) (7.89) (10.57) (9.96) (3.37) (7.02) 2.17 5.34
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Veracyte, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GRAL GRAIL, Inc. $6.1B — (loss-making) — (loss-making) +25.72% (above 0%: growing) n/m −4.95% (below 0%: shrinking) (28.12%) (388.89%) Compare
RDNT RadNet, Inc. $5.5B — (loss-making) 279× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34% Compare
SHC Sotera Health Company $5.2B 31.4× 23.7× +9.18% (above 0%: growing) +533.33% (above 0%: growing) +60.56% (above 0%: growing) 55.38% 33.23% Compare
BLLN BillionToOne, Inc. $4.9B 95.0× 99.4× +64.40% (above 0%: growing) n/m +400.65% (above 0%: growing) 70.45% 5.03% Compare
ADPT Adaptive Biotechnologies Corporation $4.1B — (loss-making) — (loss-making) +21.53% (above 0%: growing) n/m +42.04% (above 0%: growing) 71.82% (22.04%) Compare
VCYT Veracyte, Inc. $3.6B 29.9× 45.1× +15.49% (above 0%: growing) n/m +32.95% (above 0%: growing) 72.21% 15.29%
CDNA CareDx, Inc. $3.5B 29.7× 2,967× +52.23% (above 0%: growing) n/m +223.42% (above 0%: growing) 73.50% 85.81% Compare
NEO NeoGenomics, Inc. $2.2B — (loss-making) — (loss-making) +11.21% (above 0%: growing) n/m −16.18% (below 0%: shrinking) 45.56% (4.85%) Compare
WGS GeneDx Holdings Corp. $2.1B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
Median of peers $4.5B 31.4× 189× +23.26% — +18.55% 61.87% 0.09%

All 52 Diagnostics & Research stocks →

Veracyte, Inc. (VCYT) key facts

  • Strength: Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
  • Veracyte, Inc. (VCYT) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, VCYT traded at $43.12, a market capitalization of $3.6 billion.
  • Return on equity was 5.34% and debt-to-equity 0.00.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 21.08 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Veracyte, Inc. (VCYT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/VCYT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com